As 5 more biotechs file their IPOs, one Nas­daq of­fi­cial does­n't see mo­men­tum slow­ing down any­time soon

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It’s been a heck of a ride for the biotech IPO mar­ket over the last year and a half, with 2020 set­ting record fig­ures and 2021 on track to reach even greater heights. And as an­oth­er five bio­phar­mas filed their S-1s late Fri­day, one ex­pert doesn’t see a slow­down oc­cur­ring any time soon.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA